
    
      This is a single arm, prospective trial using a 2-stage Simon design, in which eligible
      patients will receive intravenous cabazitaxel for two cycles followed by response evaluation.
      Based on the pre-specified criteria of response (intra-cranial, patient will be allowed to
      continue on study drug.
    
  